23/04/2025 – AB Science announces today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia (AML) Download PDF Post navigationPreviousPrevious post:AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell diseaseNextNext post:AB Science will publish its 2024 annual financial report on May 9, 2025Related PostsAB Science provides an update on the renegotiation of loan repayment terms with its financial creditorsJune 30, 2025New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s diseaseJune 23, 2025AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036June 12, 2025AB Science announces EMA approval of Masivet shelf-life extension to 4 yearsJune 9, 2025AB Science announces the settlement delivery of its latest capital increase for €1.8 millionMay 23, 2025AB Science announces the successful completion of a EUR 1.8 million private placementMay 20, 2025
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditorsJune 30, 2025
New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s diseaseJune 23, 2025
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036June 12, 2025
AB Science announces the settlement delivery of its latest capital increase for €1.8 millionMay 23, 2025
